Suppr超能文献

低剂量吸入性糖皮质激素治疗与哮喘急诊就诊风险

Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma.

作者信息

Sin Don D, Man S F Paul

机构信息

Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2B7.

出版信息

Arch Intern Med. 2002 Jul 22;162(14):1591-5. doi: 10.1001/archinte.162.14.1591.

Abstract

BACKGROUND

Patients who visit the emergency department (ED) because of asthma frequently have a relapse. While the use of inhaled corticosteroids has been demonstrated to improve asthma symptoms and lung function, it is not clear whether their use after discharge from the ED reduces asthma relapse rates.

OBJECTIVE

To determine whether inhaled corticosteroid therapy reduces ED asthma relapse rates.

METHODS

We analyzed ED visit and medication data on patients 5 to 60 years of age who were enrolled in a government-sponsored drug plan and who visited an ED because of asthma between April 1, 1997, and March 31, 1999, in Alberta, Canada (N = 1293). Using a Cox proportional hazards model, we determined the relative risk (RR) of relapse ED visits among users and nonusers of inhaled corticosteroids after discharge from the ED. We also compared the RR of relapse ED visits across different dose categories.

RESULTS

Users of inhaled corticosteroids after ED discharge had 45% fewer relapse ED visits than did nonusers (adjusted RR, 0.55; 95% confidence interval [CI], 0.44-0.69). Low-, medium-, and high-dose therapies were associated with similar reductions in the risk of relapse ED visits: low-dose therapy (RR, 0.52; 95% CI, 0.39-0.68), medium-dose therapy (RR, 0.51; 95% CI, 0.34-0.76), and high-dose therapy (RR, 0.67; 95% CI, 0.47-0.94).

CONCLUSIONS

Inhaled corticosteroid therapy after ED discharge is associated with a significant reduction in the risk of subsequent ED visits. Low-dose therapy appears to be as effective as high-dose therapy. However, further studies are needed to determine the optimal dosing regimen for inhaled corticosteroid therapy for asthma.

摘要

背景

因哮喘前往急诊科(ED)就诊的患者经常会复发。虽然吸入性糖皮质激素的使用已被证明可改善哮喘症状和肺功能,但在急诊科出院后使用是否能降低哮喘复发率尚不清楚。

目的

确定吸入性糖皮质激素治疗是否能降低急诊科哮喘复发率。

方法

我们分析了1997年4月1日至1999年3月31日期间在加拿大艾伯塔省参加政府资助药物计划且因哮喘前往急诊科就诊的5至60岁患者的急诊科就诊和用药数据(N = 1293)。使用Cox比例风险模型,我们确定了急诊科出院后吸入性糖皮质激素使用者和非使用者中复发急诊科就诊的相对风险(RR)。我们还比较了不同剂量类别中复发急诊科就诊的RR。

结果

急诊科出院后使用吸入性糖皮质激素的患者复发急诊科就诊的次数比未使用者少45%(调整后的RR,0.55;95%置信区间[CI],0.44 - 0.69)。低剂量、中等剂量和高剂量治疗在降低复发急诊科就诊风险方面效果相似:低剂量治疗(RR,0.52;95%CI,0.39 - 0.68),中等剂量治疗(RR,0.51;95%CI,0.34 - 0.76),高剂量治疗(RR,0.67;95%CI,0.47 - 0.94)。

结论

急诊科出院后吸入性糖皮质激素治疗与后续急诊科就诊风险的显著降低相关。低剂量治疗似乎与高剂量治疗一样有效。然而,需要进一步研究来确定哮喘吸入性糖皮质激素治疗的最佳给药方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验